Orion Biotechnology
Orion Biotechnology is developing GPCR-targeted therapies to treat metabolic and immunological diseases, supported by a rapid drug discovery platform and a lead compound, OB-002, with broad applicability.
Company Overview
Orion Biotechnology is engaged in discovering and developing G Protein-Coupled Receptor (GPCR) targeted therapies aimed at treating metabolic and immunological diseases. With headquarters located at 343 Preston Street, 11th floor, Ottawa, ON K1S 1N4, Canada, the company also operates in Switzerland and Poland. Orion Biotechnology utilizes advanced precision engineering to create ligands for small protein GPCRs, aiming to develop next-generation therapeutic solutions.
GPCR-Based Therapies
Orion Biotechnology focuses on GPCR-based therapies, leveraging its innovative approach to engineer ligands, advancing the treatment of diseases such as cancer, infectious diseases, and neuroinflammatory disorders. The lead compound, OB-002, boasts best-in-class potency and wide-ranging applications. Further, the company's discovery platform, PROcisionXᵀᴹ, allows for rapid generation of leading GPCR-targeted treatments.
Drug Discovery Platform
Orion Biotechnology's PROcisionXᵀᴹ platform is one of the fastest drug discovery platforms in the industry, capable of generating first-in-class and best-in-class leads against peptide and protein GPCRs. The platform integrates streamlined phage display, multiplex chemical synthesis, and a structure-activity matrix for optimization. This innovative approach has enabled the discovery of the first-in-class molecule against the undrugged GPCR target CXCR6 within four months.
Lead Compounds and Pipeline
Orion Biotechnology's pipeline includes a range of next-generation GPCR-targeted therapeutics. Key compounds include OB-002, a GPCR analog of CCL5, OB-003 targeting CCR9 for oncology and inflammatory bowel disease, and OB-004 targeting CCR2 for oncology and inflammation. Additionally, the company has undisclosed targets in lead discovery and target validation phases for oncology and metabolic disorders, showcasing its commitment to innovation and precision medicine.
Global Research and Development
Orion Biotechnology's research and development efforts extend globally. In Poland, the subsidiary's projects are funded under the Operational Programme – Smart Growth 2014-2020, including the development of a new candidate microbicide for HIV prevention and a CCR5 immunotherapy for advanced cancer. The project for HIV transmission prevention has a total project amount of 9,928,239.50 PLN with 7,034,900.75 PLN of co-funding, while the CCR5 immunotherapy project is funded at 9,822,015.00 PLN with 6,873,131.75 PLN coming from co-funding.